This federal Project Grant award of $542,094.00 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The funding supports research at the University of Kentucky Research Foundation to evaluate the use of liposomal azithromycin as a treatment for cardiac inflammation. The key objectives are to assess the efficacy and safety of this novel therapeutic approach, and determine its potential to mitigate immune responses and reduce cardiac damage. The research aims to advance understanding of the mechanisms and optimal treatment of cardiovascular diseases. The award period runs from March 2025 through February 2027.
Generated 3/25/25, 4:18 AM